Evidence map›Paper›PMID 27174834›Full record

ArticleInternational journal of epidemiology2016

Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China.

Wenzhou Yu, Dawei Liu, Jingshan Zheng, Yanmin Liu, Zhijie An, Lance Rodewald, Guomin Zhang, Qiru Su, Keli Li, Disha Xu and 15 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in International journal of epidemiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
10.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Reforms in China's Vaccine Administration-From the Perspective of New Governance Approach.International journal of environmental research and public health · 2023
    Review
  11. Article
  12. Hepatitis B eradication: vaccine as a key player.American journal of translational research · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. A New Strategy for Cervical Cancer Prevention Among Chinese Women: How Much Do They Know and How Do They React Toward the HPV Immunization?Journal of cancer education : the official journal of the American Association for Cancer Education · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 1 institution in 1 country.

Wenzhou YuNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and.
Dawei LiuNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and.
Jingshan ZhengNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and.
Yanmin LiuNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and.
Zhijie AnNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and.
Lance RodewaldWorld Health Organization Office in China, Beijing, China.
Guomin ZhangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Qiru SuNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Keli LiNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Disha XuNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Fuzhen WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Ping YuanNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Wei XiaWorld Health Organization Office in China, Beijing, China hqwang@vip.sina.com.
Guijun NingNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Hui ZhengNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Yaozhu ChuNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Jian CuiNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Mengjuan DuanNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Lixin HaoNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Yuqing ZhouNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Zhenhua WuNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Xuan ZhangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Fuqiang CuiNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Li LiNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Huaqing WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China and hqwang@vip.sina.com.
Chinese Center For Disease Control and Prevention · CN

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundChina reduced hepatitis B virus (HBV) infection by 90% among children under 5 years old with safe and effective hepatitis B vaccines (HepB). In December 2013, this success was threatened by widespread media reports of infant deaths following HepB administration. Seventeen deaths and one case of anaphylactic shock following HBV vaccination had been reported.

methodsWe conducted a telephone survey to measure parental confidence in HepB in eleven provinces at four points in time; reviewed maternal HBV status and use of HepB for newborns in birth hospitals in eight provinces before and after the event; and monitored coverage with hepatitis B vaccine and other programme vaccines in ten provinces.

resultsHepB from the implicated company was suspended during the investigation, which showed that the deaths were not caused by HepB vaccination. Before the event, 85% respondents regarded domestic vaccines as safe, decreasing to 26.7% during the event. During the height of the crisis, 30% of parents reported being hesitant to vaccinate and 18.4% reported they would refuse HepB. Use of HepB in the monitored provinces decreased by 18.6%, from 53 653 doses the week before the event to 43 688 doses during the week that Biokangtai HepB was suspended. Use of HepB within the first day of life decreased by 10% among infants born to HBsAg-negative mothers, and by 6% among infants born to HBsAg-positive mothers. Vaccine refusal and HepB birth dose rates returned to baseline within 2 months; confidence increased, but remained below baseline.

conclusionsThe HBV vaccine event resulted in the suspension of a safe vaccine, which was associated with a decline of parental confidence, and refusal of vaccination. Suspension of a vaccine can lead to loss of confidence that is difficult to recover. Timely and credible investigation, accompanied by proactive outreach to stakeholders and the media, may help mitigate negative impact of future coincidental adverse events following immunization.

Indexed as

Immunization ProgramsInfant DeathVaccinationAdverse Drug Reaction Reporting SystemsCause of DeathChildChinaDrug-Related Side Effects and Adverse ReactionsFemaleHepatitis BHepatitis B AntibodiesHepatitis B VaccinesHumansInfantInfant, NewbornMaleHepatitis B AntibodiesHepatitis B Vaccinescoincidental deathcommunicationHepatitis B vaccinationvaccine confidence

Identifiers

PMID27174834
OpenAlexW2394134574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.